Physician profile
Sima Salman
NPI 1356581680
$1,881.51
in general payments reported to CMS, 2019-2025
31 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $83.69 · 2021: $169 · 2022: $283 · 2023: $275 · 2024: $434 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $462.21 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.67 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $116.13 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $108.96 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $104.67 | 2020-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $86.94 | 2022-2024 | Ubrelvy |
| Nestle Healthcare Nutrition INC. | $74.63 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $70.12 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $55.94 | 2022-2023 | Shingrix |
| Valeritas, INC. | $51.68 | 2019 | |
| Merck Sharp & Dohme LLC | $50.18 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Dexcom, INC. | $47.43 | 2023-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $46.94 | 2024-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $40.92 | 2019-2020 | |
| Vifor Pharma, INC. | $36.86 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $30.12 | 2019 | |
| Philips North America LLC | $29.90 | 2022-2024 | (5044) Mcot |
| Pfizer INC. | $27.99 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $26.45 | 2023 | Quviviq |
| Nevro Corp. | $26.28 | 2023 | Senza |
| Teva Pharmaceuticals USA, INC. | $24.96 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.60 | 2019 | |
| Daiichi Sankyo INC. | $18.48 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.29 | 2021 | |
| Irhythm Technologies, INC. | $17.19 | 2024 | Zio Monitor, Zio Xt Patch |
| Aimmune Therapeutics, INC. | $16.81 | 2025 | Zenpep |
| Tactile Systems Technology INC | $14.64 | 2023 | Flexitouch Plus, Entre Plus |
| Novartis Pharmaceuticals Corporation | $13.50 | 2022 | |
| Horizon Therapeutics Plc | $12.58 | 2021 | |
| Advanced Respiratory, INC | $11.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sima Salman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.